Some countries in the European Union have temporarily suspended the use of the AstraZeneca COVID-19 vaccine as a precautionary measure based on reports of rare blood coagulation disorders in persons who had received the vaccine.
Other countries in the EU – having considered the same information – have decided to continue using the vaccine in their immunization programmes.
In reaction to these developments, the World Health Organization says it is routine for countries to signal potential adverse events following immunization in extensive vaccination campaigns.
READ ALSO: EU Plans Digital COVID-19 Certificate For Safe Travel
The WHO in a communique on Wednesday however noted that “this does not necessarily mean that the events are linked to the vaccination itself, but it is good practice to investigate them. It also shows that the surveillance system works and that effective controls are in place.”
While stressing that vaccination against COVID-19 will not reduce illness or deaths from other causes, the WHO said it is in regular contact with the European Medicines Agency and regulators around the world for the latest information on COVID-19 vaccine safety.
“The WHO Global Advisory Committee on Vaccine Safety is carefully assessing the latest available safety data for the AstraZeneca vaccine. Once that review is completed, WHO will immediately communicate the findings to the public,” the organization’s statement further read.
WHO emphasized that at the moment, it considers that the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.
